Angiogenesis is required in cancer, including gynecological cancers, for the growth of primary tumors and secondary metastases. Development anti-angiogenesis therapy cancers improvement its efficacy have been a major focus fundamental clinical research. However, survival benefits current anti-angiogenic agents, such as bevacizumab, patients with are modest. Therefore, better understanding angio...

Vascular endothelial growth factors (VEGFs) are the family of extracellular signaling proteins involved in processes angiogenesis. VEGFA overexpression and altered regulation pathways lead to pathological angiogenesis, which contributes progression various diseases, such as age-related macular degeneration cancer. Monoclonal antibodies decoy receptors have been extensively used anti-angiogenic ...

With growing interest in cancer therapeutics, anti-angiogenic therapy has received considerable attention and is widely administered in several types of human cancers. Nonetheless, this type of therapy may induce multiple signaling pathways compared with cytotoxics and lead to worse outcomes in terms of resistance, invasion, metastasis, and overall survival (OS). Moreover, there are important c...

background: mesenchymal stem cells (mscs) are recently introduced as novel immunological gene carriers for treatment of cancer. it is believed that balance between the expression of angiogenic and anti-angiogenic factors, such as sdf-1 and ip-10, may regulate neovascularization within the tumor. methods: in this study, we compared the expression of important tumor promoting mediators in ip-10-t...

BACKGROUND While there is significant interest in combining anti-angiogenesis therapy with conventional anti-cancer treatment, clinical trials have as of yet yielded limited therapeutic gain, mainly because mechanisms of anti-angiogenic therapy remain to a large extent unknown. Currently, anti-angiogenic tumor therapy is conceptualized to either "normalize" dysfunctional tumor vasculature, or t...

Despite advances in surgery, radiation therapy, and chemotherapy, patients with cancer have a poor prognosis. Sustained aberrant tumor angiogenesis and metastasis is a major obstacle for effective cancer treatment. Just a few years ago, few would argue that one of the key success stories of the modern cancer medicine were the anti-angiogenic drugs targeting the vascular endothelial growth facto...

Glioblastoma (GBM) is a rapidly progressive brain cancer that exploits the neural microenvironment, and particularly blood vessels, for selective growth and survival. Anti-angiogenic agents such as the vascular endothelial growth factor-A (VEGF-A) blocking antibody bevacizumab yield short-term benefits to patients due to blood vessel regression and stabilization of vascular permeability. Howeve...

Inhibitors of angiogenesis and radiation induce compensatory changes in the tumor vasculature both during and after treatment cessation. To assess the responses to irradiation and vascular endothelial growth factor-receptor tyrosine kinase inhibition (by the vascular endothelial growth factor tyrosine kinase inhibitor PTK787/ZK222854), mammary carcinoma allografts were investigated by vascular ...

Tumor microenvironments are characterized by decreased oxygen and nutrition due to the rapid and progressive nature of tumors and also stresses induced by several anti-tumor therapies. These intense cell stressors trigger a protective cell survival mechanism heralded by the unfolded protein response (UPR). The UPR is induced by an accumulation of unfolded proteins in the endoplasmic reticulum (...